Glenmark settles dispute with Forest Laboratories

21 December 2015 | News | By BioSpectrum Bureau

Glenmark will have the option to market and distribute its Milnacipran Hydrochloride tablets

Glenmark Pharmaceuticals has announced that they have entered into a settlement agreement with Forest Laboratories and Royalty Pharma Collection Trust, to settle and dismiss the outstanding patent litigation related to Glenmark's Abbreviated New Drug Application for Milnacipran Hydrochloride 12.5 milligram, 25 milligram, 50 milligram, and 100 milligram tablets, the generic version of Forest's Savella.

Under the terms of the Settlement Agreement, Glenmark will have the option to market and distribute its Milnacipran Hydrochloride tablets or an authorized generic version of Savella tablets. Other terms of the Settlement Agreement are confidential.

According to IMS Health sales data for the 12 month period ending October 2015, Savella achieved annual sales of approximately $134.7 million.